Advertisement
Table 1 Baseline demographics and patient characteristics
| Characteristic | CZP ITT population (n = 492) | Week 24 CZP completers (n = 342) | Week 24 placebo completers (n = 17) | Dose-reduction population (n = 369) | Safety population (n = 612) |
|---|---|---|---|---|---|
| Age, mean (SD), years | 52.0 (11.4) | 51.6 (11.6) | 53.2 (16.0) | 51.1 (11.3) | 51.9 (11.5) |
| Gender, % female | 80.9 | 82.7 | 82.4 | 81.8 | 81.5 |
| Disease duration, mean (SD), years | 6.3 (4.2) | 6.5 (4.2) | 3.5 (2.3) | 6.2 (4.2) | 6.2 (4.2) |
| RF-positive (≥14 IU/ml), % | 76.5 | 75.4 | 88.2 | 73.7 | 76.9 |
| Tender/painful joint count, mean (SD) | 30.1 (14.2) | 30.5 (14.5) | 33.4 (12.1) | 29.9 (13.9) | 30.2 (14.0) |
| Swollen joint count, mean (SD) | 20.7 (9.9) | 20.7 (10.1) | 24.2 (8.2) | 20.6 (10.1) | 21.0 (9.9) |
| Pain VAS, mean (SD) | 61.2 (19.7) | 60.6 (19.8)a | 59.1 (21.6) | 61.2 (19.5)b | 60.9 (20.3)c |
| HAQ-DI, mean (SD) | 1.6 (0.6) | 1.6 (0.6) | 1.6 (0.5) | 1.6(0.6) | 1.6 (0.6)d |
| DAS28(ESR), median (min, max) | 6.8 (4, 9)e | 6.8 (5, 9)a | 7.1 (6, 8) | 6.8 (5, 9)b | 6.9 (4, 9)f |
